Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations : Invited short review

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations ; day:8 ; month:2 ; year:2024 ; pages:1-6
Magazine of European Medical Oncology ; (8.2.2024), 1-6

Creator: Sharapova, Yana
Loges, Sonja
Janning, Melanie

Contributor: SpringerLink (Online service)

DOI: 10.1007/s12254-024-00960-2

URN: urn:nbn:de:101:1-2404170729053.668980370549

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 2025-08-14T11:04:09+0200

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Sharapova, Yana
Loges, Sonja
Janning, Melanie
SpringerLink (Online service)

Other Objects (12)

USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC

Oncogenic alterations in advanced NSCLC: a molecular super-highway

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC

Oncogenic alterations in advanced NSCLC: a molecular super-highway

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC

Oncogenic alterations in advanced NSCLC: a molecular super-highway

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations : Invited short review

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC

Oncogenic alterations in advanced NSCLC: a molecular super-highway

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC

Oncogenic alterations in advanced NSCLC: a molecular super-highway

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC

Oncogenic alterations in advanced NSCLC: a molecular super-highway

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Related objects

Reset password